A Phase I/II Study Evaluating Hepatic Embolization with Bumetanide to Treat Inoperable Liver Cancer

Full Title

Phase I/II study of Transarterial Hepatic Embolization with Bumetanide in Unresectable Hepatocellular Carcinoma

Purpose

Transarterial embolization (TAE) is a common treatment for people with liver cancer who cannot have surgery. With this approach, small particles are injected to “plug up” the arteries supplying blood to the tumor, starving cancer cells of the oxygen they need to grow and survive.

In this study, researchers want to see if adding the diuretic bumetanide to TAE makes this treatment more effective against liver cancer. Bumetanide may inhibit tumor growth by slowing tumor metabolism.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable hepatocellular carcinoma and be planning to have TAE as part of their therapy.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Hooman Yarmohammadi at 212-639-2234.

Protocol

17-141

Phase

I/II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator